

Prof. ÖZLEN ATUĞ

Personal Information

Email: ozlen.atug@marmara.edu.tr

Other Email: ozlenatug@hotmail.com

Web: <https://avesis.marmara.edu.tr/ozlen.atug>

International Researcher IDs

ORCID: 0000-0001-9695-9416

Yoksis Researcher ID: 178540

Education

Post Doctorate, Tulane University, Tulane University School of Medicine, Department of Gastroenterology&Hepatology, United States Of America 2004 - 2006

Post Doctorate of Medicine, Marmara University, School of Medicine, Internal Medical Sciences, Turkey 2000 - 2004

Expertise In Medicine, Marmara University, School of Medicine, Internal Medical Sciences, Turkey 1995 - 2000

Undergraduate, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Turkey 1988 - 1994

Foreign Languages

English, B2 Upper Intermediate

Certificates, Courses and Trainings

Health&Medicine, Basic Good Clinical Practice (GCP) Certificate , International Training Academy of Pharmaceutical Sciences (ITAPS), 2007

Health&Medicine, Marmara Üniversitesi Tıp Fakültesi, Deney Hayvanı Kullanımı ve Etik Yaklaşım Kursu Sertifikası, Marmara Üniversitesi, 2003

Dissertations

Post Doctorate of Medicine, İnflamatuar barsak hastalıklarında peroksizom proliferator aktivite resptör - gamma (PPAR- γ) geninde Pro12Ala polimorfizmin sıklığı, Marmara University, School of Medicine, Internal Medical Sciences, 2004

Expertise In Medicine, İnflamatuar barsak hastalıklarında ısı şoku proteini 60 ve 72'nin (HSP 60, HSP 72) intestinal ekspresyonu ve 5-ASA tedavisinin etkileri, Marmara University, School of Medicine, Internal Medical Sciences, 2000

Research Areas

Health Sciences

Academic Positions

Professor, Marmara University, School of Medicine, Internal Medical Sciences, 2016 - Continues
Associate Professor, Marmara University, School of Medicine, Internal Medical Sciences, 2010 - 2016
Expert, Marmara University, School of Medicine, Internal Medical Sciences, 2006 - 2010
Expert, Tulane University, School Of Medicine, Department Of Gastroenterology And Hepatology, 2004 - 2006
Expert, Marmara University, School of Medicine, Internal Medical Sciences, 2000 - 2004
Research Assistant, Marmara University, School of Medicine, Internal Medical Sciences, 1995 - 2000

Academic and Administrative Experience

Head of Department, Marmara University, School of Medicine, Internal Medical Sciences, 2020 - Continues
Enstitü Yönetim Kurulu Üyesi, Marmara University, School of Medicine, Internal Medical Sciences, 2011 - 2020
Assistant Director of the Institute, Marmara University, Institute of Gastroenterology, 2011 - 2012

Supervised Theses

ATUĞ Ö., ATAGÜNDÜZ M. P., Spondiloartropatili hastalarda kronik diyare ve intestinal inflamatuvar hastalık ilişkisinin saptanması, Expertise In Medicine, İ.ERGENÇ(Student), 2018
ATUĞ Ö., ATAGÜNDÜZ M. P., Aksiyal spondiloartrit hastalarında inflamatuvar bağırsak hastalığı birlikteliğinin radyografik hasara etkisinin değerlendirilmesi, Expertise In Medicine, F.BALUKEN(Student), 2018

Journal articles indexed in SCI, SSCI, and AHCI

- I. **Response to “Utility of SARC-F for screening for sarcopenia in ulcerative colitis”**
Ergenc I., Ismail Basa C., Uzun A., Sahin S., KANI H. T., Aslan R., TUFAN ÇİNÇİN A., KASIMAY Ö., ATUĞ Ö., Alahdab Y. Ö.
Nutrition in Clinical Practice, vol.39, no.5, pp.1272-1273, 2024 (SCI-Expanded)
- II. **High prevalence of muscle weakness and probable sarcopenia in patients with inflammatory bowel disease**
Ergenc I., Ismail Basa C., Uzun A., Sahin S., KANI H. T., Aslan R., Tufan A., KASIMAY Ö., ATUĞ Ö., Alahdab Y. Ö.
Nutrition in Clinical Practice, vol.39, no.3, pp.557-567, 2024 (SCI-Expanded)
- III. **Improving the Computer-Aided Estimation of Ulcerative Colitis Severity According to Mayo Endoscopic Score by Using Regression-Based Deep Learning**
Polat G., Kani H. T., Ergenc I., ÖZEN ALAHDAB Y., TEMİZEL A., ATUĞ Ö.
INFLAMMATORY BOWEL DISEASES, vol.29, pp.1431-1439, 2023 (SCI-Expanded)
- IV. **RE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy**
Ergenç İ., KANI H. T., KARABACAK M., CÖMERT ÖZER E., Mehdiyev S., Jafarov F., ABACAR K. Y., KUTLUĞ AĞAÇKIRAN S., SEVİK G., Aslan R., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.34, no.3, pp.310, 2023 (SCI-Expanded)
- V. **Improvement of Work Productivity and Quality of Life with Anti-Tumor Necrosis Factor Treatment Used in Crohn's Disease in Routine Clinical Practice in Turkey**
TÖRÜNER M., BAŞARANOĞLU M., ATUĞ Ö., Senturk O., Akyuz F., Cekic C., Over Hamzaoglu H., Tekin F., Sezgin O., AKPINAR H., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.33, no.5, pp.406-413, 2022 (SCI-Expanded)
- VI. **Evaluation of endoscopic mayo score with an artificial intelligence algorithm**
Kani H. T., Ergenc I., Polat G., Alahdab Y. O., TEMİZEL A., Atug O.

JOURNAL OF CROHNS & COLITIS, vol.15, 2021 (SCI-Expanded)

VII. **Correlation between physician disease assessment in Ulcerative Colitis and burden of disease: ICONIC 2-year data of 120 patients in Turkey**

Sezgin O., Atug O., Gonen C., Can G., Duman A. E., Erzin Y. Z., Yurci M. A., Alkim C., Ozcelik N. G. U., Yildirim B., et al.
JOURNAL OF CROHNS & COLITIS, vol.15, 2021 (SCI-Expanded)

VIII. **Hepatitis B reactivation under biologic therapy in patients with HBsAg negative phase of chronic HBV infection**

Ergenc I., Kani H. T., Karabacak M., Ozer E. C., Mehdiyev S., Jafarov F., Abacar K. Y., Agackiran S. K., Sevik G. S., Oner F. A., et al.

JOURNAL OF CROHNS & COLITIS, vol.15, 2021 (SCI-Expanded)

IX. **Depression and anxiety have unique contributions to somatic complaints in depression, irritable bowel syndrome and inflammatory bowel diseases**

YANARTAŞ Ö., Kani H. T., Kani A., Akca Z. N. D., Akca E., Ergun S., Tezcan N., ATUĞ Ö., Imeryuz N., Sayar K.
PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, vol.29, no.4, pp.418-426, 2019 (SCI-Expanded)

X. **Effectiveness of "Hospital Anxiety and Depression Scale" for the screening of the psychiatric treatment need in outpatients with Inflammatory Bowel Diseases**

Yanatas O., Kani H. T., Banzragch M., Bicakci E., Kuscu K., Atug O., Imeryuz N., Akin H.
JOURNAL OF CROHNS & COLITIS, vol.9, 2015 (SCI-Expanded)

XI. **No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects**

Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.25, no.6, pp.639-643, 2014 (SCI-Expanded)

XII. **Sexual dysfunction in inflammatory bowel disease patients**

Yanartas O., Kani H. T., Banzragch M., Bicakci E., Kani A., Atug O., Kuscu K., Imeryuz N., Akin H.
JOURNAL OF CROHNS & COLITIS, vol.8, 2014 (SCI-Expanded)

XIII. **Vitamin D deficiency in inflammatory bowel disease patients**

Kani H. T., Demircan N., Yazici D., Bicakci E., Banzragch M., Atug O., Hamzaoglu H. O., Imeryuz N., Akin H.
JOURNAL OF CROHNS & COLITIS, vol.8, 2014 (SCI-Expanded)

XIV. **Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease**

YILMAZ Y., Ozturk O., Alandab Y., Senates E., ÇOLAK Y., Doganay H. L., Coskunpinar E., Oltulu Y. M., EREN F., ATUĞ Ö., et al.

DIGESTIVE AND LIVER DISEASE, vol.45, no.1, pp.58-62, 2013 (SCI-Expanded)

XV. **Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease**

Eren F., Kurt R., Ermis F., Atug Ö., Imeryuz N., Yilmaz Y.

Clinical Biochemistry, vol.45, pp.655-658, 2012 (SCI-Expanded)

XVI. **Preliminary evidence of an association between the functional c-kit rs6554199 polymorphism and achalasia in a Turkish population**

Alahdab Y., Eren F., Giral A., Gunduz F., Kedrah A. E., Atug O., Yilmaz Y., Kalayci O., Kalayci C.
NEUROGASTROENTEROLOGY AND MOTILITY, vol.24, no.1, pp.27-30, 2012 (SCI-Expanded)

XVII. **Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity**

Yilmaz Y., Yonal O., Eren F., Atug O., Hamzaoglu H. O.

Journal of Crohn's and Colitis, vol.5, no.5, pp.402-406, 2011 (SCI-Expanded)

XVIII. **Association Between The Presence of Brown Adipose Tissue and Nonalcoholic Fatty Liver Disease in Adult Humans**

Yilmaz Y., Ones T., Purnak T., Kurt R., Ozguven S., Atug O., Turoglu H., Imeryuz N.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

XIX. **Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans.**

- Yilmaz Y., Ones T., Purnak T., Ozguven S., Kurt R., Atug O., Turoglu H. T., Imeryuz N.
Alimentary pharmacology & therapeutics, vol.34, no.3, pp.318-23, 2011 (SCI-Expanded)
- XX. **Association between bactericidal/permeability increasing protein (BPI) gene polymorphism (Lys216Glu) and inflammatory bowel disease**
Akin H., Tahan G., Ture F., EREN F., ATUĞ Ö., Tahan V., Hamzaoglu I., Imeryuz N., Tozun N., Hamzaoglu H. O.
JOURNAL OF CROHNS & COLITIS, vol.5, no.1, pp.14-18, 2011 (SCI-Expanded)
- XXI. **R72P Polymorphism of TP53 in Ulcerative Colitis Patients is Associated with the Incidence of Colectomy, Use of Steroids and the Presence of a Positive Family History**
EREN F., AKKİPRİK M., ATUĞ Ö., Sonmez O., Tahan G., Ozdemir F., Hamzaoglu H. O., ÇELİKEL Ç., Imeryuz N., Avsar E., et al.
PATHOLOGY & ONCOLOGY RESEARCH, vol.16, no.4, pp.563-568, 2010 (SCI-Expanded)
- XXII. **Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance**
Yilmaz Y., Ulukaya E., Atug Ö., Dolar E.
European Journal of Gastroenterology and Hepatology, vol.21, pp.1247-1251, 2009 (SCI-Expanded)
- XXIII. **The effects of pegylated interferon alpha 2b on bile-duct ligation induced liver fibrosis in rats**
Canbakan B., Akin H., Tahan G., Tarcin O., Eren F., Atug O., Tahan V., Imeryuz N., Yapicier O., Avsar E., et al.
ANNALS OF HEPATOLOGY, vol.8, no.3, pp.234-240, 2009 (SCI-Expanded)
- XXIV. **Awareness of hepatitis C virus transmission routes among patients, their household contacts and health care staff: Does perception match the reality?**
Tiftikci A., ATUĞ Ö., Tozun N.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.20, no.2, pp.104-107, 2009 (SCI-Expanded)
- XXV. **Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C**
ATUĞ Ö., Akin H., YILMAZ Y., Sari M., Tozun N.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.18, no.2, pp.256, 2009 (SCI-Expanded)
- XXVI. **Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease**
YILMAZ Y., ULUKAYA E., Gul O. O., Arabul M., Gul C. B., ATUĞ Ö., YILMAZTEPE ORAL A., Aker S., Dolar E.
CLINICAL BIOCHEMISTRY, vol.42, no.9, pp.802-807, 2009 (SCI-Expanded)
- XXVII. **Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats**
Tahan V., ATUĞ Ö., Akin H., EREN F., Tahan G., Tarcin O., UZUN H., Ozdogan O., Tarcin O., Imeryuz N., et al.
JOURNAL OF PINEAL RESEARCH, vol.46, no.4, pp.401-407, 2009 (SCI-Expanded)
- XXVIII. **Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis**
Tiftikci A., ATUĞ Ö., YILMAZ Y., EREN F., Ozdemir F. T., Yapali S., Ozdogan O., ÇELİKEL Ç., Imeryuz N., Tozun N.
ARCHIVES OF MEDICAL RESEARCH, vol.40, no.4, pp.294-298, 2009 (SCI-Expanded)
- XXIX. **Critical pH Level of Lye (NaOH) for Esophageal Injury**
ATUĞ Ö., Dobrucali A., Orlando R. C.
DIGESTIVE DISEASES AND SCIENCES, vol.54, no.5, pp.980-987, 2009 (SCI-Expanded)
- XXX. **Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease**
YILMAZ Y., ATUĞ Ö., Yonal O., DUMAN D., Ozdogan O., Imeryuz N., Kalayci C.
MEDICAL SCIENCE MONITOR, vol.15, no.4, 2009 (SCI-Expanded)
- XXXI. **Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry**
ULUKAYA E., YILMAZ Y., Moshkovskii S., Karpova M., Pyatnitskiy M., ATUĞ Ö., Dolar E.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.44, no.12, pp.1471-1476, 2009 (SCI-Expanded)
- XXXII. **Clinical Characteristics of Inflammatory Bowel Disease in Turkey A Multicenter Epidemiologic Survey**
Tozun N., ATUĞ Ö., Imeryuz N., Hamzaoglu H. O., Tiftikci A., Parlak E., Dagli U., Ulker A., HÜLAGÜ S., AKPINAR H., et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.43, no.1, pp.51-57, 2009 (SCI-Expanded)

- XXXIII. **Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR γ) gene in inflammatory bowel disease**
 ATUĞ Ö., Tahan V., EREN F., Tiftikci A., Imeryuz N., Hamzaoglu H. O., Tozun N.
 Journal of Gastrointestinal and Liver Diseases, vol.17, no.4, pp.433-437, 2008 (SCI-Expanded)
- XXXIV. **Pro12Ala Polymorphism in the Peroxisome Proliferator-Activated Receptor-gamma (PPAR gamma) Gene in Inflammatory Bowel Disease**
 ATUĞ Ö., Tahan V., EREN F., Tiftikci A., Imeryuz N., Hamzaoglu H. O., Tozun N.
 JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, vol.17, no.4, pp.433-437, 2008 (SCI-Expanded)
- XXXV. **Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study**
 ATUĞ Ö., GİRAL A., Kalayci C., Dolar E., Isitan F., Oguz D., Ovunc O., ÖZGÜR O.
 ADVANCES IN THERAPY, vol.25, no.6, pp.552-566, 2008 (SCI-Expanded)
- XXXVI. **Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis**
 ATUĞ Ö., Hamzaoglu H., Tahan V., Alican I., Kurtkaya O., Elbuken E., Ozdogan O., Tozun N.
 DIGESTIVE DISEASES AND SCIENCES, vol.53, no.2, pp.481-485, 2008 (SCI-Expanded)
- XXXVII. **Detection of Helicobacter pylori in bladder biopsy specimens of patients with interstitial cystitis by polymerase chain reaction**
 Atug F., Turkeri L., Atug O., Cal C.
 UROLOGICAL RESEARCH, vol.32, no.5, pp.346-349, 2004 (SCI-Expanded)

Articles Published in Other Journals

- I. **MICROSATELLITE INSTABILITY IN THE INFLAMED AND NON-NEOPLASTIC COLONIC MUCOSA IN ULCERATIVE COLITIS**
 ATUĞ Ö., AKKİPRİK M., EREN F., TIFTIKCI A., Ozdemir F. T., Asicioglu F., Hamzaoglu H. O., Tozun N.
 MARMARA MEDICAL JOURNAL, vol.22, no.1, pp.12-18, 2009 (ESCI)

Papers Presented at Peer-Reviewed Scientific Conferences

- I. **Class Distance Weighted Cross-Entropy Loss for Ulcerative Colitis Severity Estimation**
 Polat G., Ergenc I., KANI H. T., ÖZEN ALAHDAB Y., ATUĞ Ö., TEMİZEL A.
 26th Annual Conference on Medical Image Understanding and Analysis (MIUA), Cambridge, Canada, 27 - 29 July 2022, vol.13413, pp.157-171, (Full Text)
- II. **MR-Enterography Findings of Intestinal Inflammation in Spondyloarthritis with high faecal calprotectin levels.**
 Ergenç İ., Uner E., ERGELEN R., HAKLAR G., İMERYÜZ N., ATUĞ Ö., ATAGÜNDÜZ M. P.
 Congress of the European-League-Against-Rheumatism (EULAR), 13 - 16 June 2018, (Full Text)
- III. **MR - ENTEROGRAPHY FINDINGS OF INTESTINAL INFLAMMATION IN SPONDYLOARTHRITIS WITH HIGH FAECAL CALPROTECTIN LEVELS**
 Ergenc I., Uner E., Ergelen R., Haklar G., Imeryuz N., Atug O., Atagunduz P.
 Congress of the European-League-Against-Rheumatism (EULAR), Amsterdam, Netherlands, 13 - 16 June 2018, vol.77, pp.808, (Summary Text)
- IV. **Bactericidal permeability increasing protein has no effect on remission of ulcerative colitis**
 EREN F., eroğlu k., Banzragch M., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., YILMAZ Y., ATUĞ Ö., İMERYÜZ N., AKIN H.
 The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japan, 7 - 09 July 2016
- V. **MT ND5 gene variants have both protective and risk factor for inflammatory bowel disease**
 Eren F., Safarova C., Gündüz F., Özen Alahdab Y., Kurt R., Yılmaz Y., Atug Ö., İmeryüz N., Akın H.

The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japan, 7 - 09 July 2016, (Summary Text)

- VI. **THE EPIDEMIOLOGY OF THE RHEUMATIC MANIFESTATIONS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE: THE PRELIMINARY DATA FROM A HOSPITAL-BASED COHORT STUDY IN ISTANBUL**
Cakir N., Imeryuz N., Atug O., Akin H.
Annual European Congress of Rheumatology (EULAR), London, Canada, 8 - 11 June 2016, vol.75, pp.1255-1256, (Summary Text)
- VII. **The effects of psychiatric treatment in patient with inflammatory bowel disease a prospective study**
YANARTAŞ Ö., Kani H. T., Biçakçı E., BEZ Y., BANZRAGCH M., DADALI Z., KILIÇ İ., ATUĞ Ö., KUŞÇU K., İMERYÜZ N., et al.
11th Congress of ECCO Inflammatory Bowel Disease, 16 - 19 March 2016
- VIII. **Ülseratif kolitin hastalık aktivitesi bakterisidal permeabilite artırıcı protein BPI düzeyi ile ilişkilidir**
EREN F., eroğlu k., banzragch m., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., YILMAZ Y., ATUĞ Ö., İMERYÜZ N., AKIN H.
32. Ulusal Gastroenetroloji Haftası, Turkey, 25 - 29 November 2015
- IX. **İNFLAMMATUAR BARSAK HASTALIĞI OLGULARINDA PSİKİYATRİK HASTALIKLAR VE TEDAVİ SONUÇLARI**
YANARTAŞ Ö., KANI H. T., BIÇAKÇI E., BEZ Y., BANZRAGCH M., DADALI Z., KILIÇ İ., KUŞÇU K., ATUĞ Ö., İMERYÜZ N., et al.
51. Ulusal Psikiyatri Kongresi, Turkey, 25 - 29 November 2015, vol.26, pp.13
- X. **Gender alters the clinical features of common anorectal disorders**
Tokay S., Atug O., Akin H., Imeryuz N.
NeuroGASTRO Conference, İstanbul, Turkey, 4 - 06 June 2015, vol.27, pp.103-104, (Summary Text)
- XI. **Contribution of the Hospital Anxiety and Depression Scale for the Prediction of Psychiatric Disorder Diagnosis in IBD Outpatient Clinics and the Results of the Treatment**
YANARTAŞ Ö., BIÇAKÇI E., KANI H. T., MUNKHTSETSEG B., ŞENKAL Z., KUŞÇU K., ATUĞ Ö., İMERYÜZ N., AKIN H.
Digestive Diseases Week 2015, Washington, D.C., United States, United States Of America, 16 - 19 May 2015, vol.148, pp.840-0
- XII. **Effectiveness of Hospital Anxiety and Depression Scale for the screening of the psychiatric treatment need in outpatients with Inflammatory Bowel Diseases**
YANARTAŞ Ö., KANI H. T., BANZRAGCH M., BIÇAKÇI E., KUŞÇU K., ATUĞ Ö., İMERYÜZ N., AKIN H.
EUROPEAN CHRON'S AND COLITIS ORGANISATIONS 2015, BARCELONA, Barcelona, Spain, 18 May - 21 February 2015
- XIII. **HASTANE ANKSİYETE VE DEPRESYON ÖLÇEĞİ İNFLAMATUAR BARSAK HASTALIĞI OLGULARINDA TEDAVİ GEREKSİNİMİNİ NE ÖLÇÜDE BELİRLİYOR**
YANARTAŞ Ö., KANI H. T., BANZRAGCH M., BIÇAKÇI E., KUŞÇU K., ATUĞ Ö., İMERYÜZ N., AKIN H.
11. ULUSAL HEPATO GASTROENTEROLOJİ KONGRESİ, Turkey, 24 - 28 September 2014
- XIV. **Sexual dysfunction in inflammatory bowel disease patients**
YANARTAŞ Ö., KANI H. T., BANZRAGCH M., BIÇAKÇI E., SAKALLI KANI A., ATUĞ Ö., KUŞÇU K., İMERYÜZ N., AKIN H.
9th CONGRESS OF ECCO, 20 - 22 February 2014, pp.119
- XV. **PRELIMINARY EVIDENCE OF A REDUCED SERUM LEVEL OF FIBROBLAST GROWTH FACTOR 19 IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE**
Eren F., Kurt R., Ermis F., Atug O., Imeryuz N., Yilmaz Y.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, vol.58, (Summary Text)
- XVI. **MELATONIN AMELIORATES METHIONINE CHOLINE DEFICIENT DIET INDUCED NONALCOHOLIC STEATOHEPATITIS IN RATS**
Tahan V., ATUĞ Ö., Akin H., EREN F., Tahan G., Tarcin Ö., Uzun H., ÖZDOĞAN O. C., Tarcin O., Imeryuz N., et al.
60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 30 October - 03 November 2009, vol.50, (Summary Text)
- XVII. **PLASMA LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (SRAGE) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE**

Yilmaz Y., Ulukaya E., Gul O. O., Arabul M., Gul C. B., Atug O., Oral A. Y., Dolar E.

44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Copenhagen, Denmark, 22 - 26 April
2009, vol.50, (Summary Text)

Metrics

Publication: 68

Citation (WoS): 503

Citation (Scopus): 635

H-Index (WoS): 14

H-Index (Scopus): 14

Non Academic Experience

Tulane University School of Medicine Department of Gastroenterology and Hepatology, New Orleans, Louisiana, USA,
Postdoctoral fellow